SEC Form 4 · accession 0001005201-19-000005
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel A. Peisert
Officer — SVP and CFO
Period of report
Feb 6, 2019
Accepted (ET)
Feb 7, 2019 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | M | 6,700 | $0.00 | A | 17,675 | D | |
| Common StockF1 | Feb 6, 2019 | F | 2,319 | $4.48 | D | 15,356 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F2,F3 | — | Feb 6, 2019 | M | 6,700 | D | — | Feb 6, 2021 | Common Stock | 6,700 | 13,400 | D |
Explanation of responses
- F1Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
- F2Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
- F3These restricted stock units are scheduled to vest 33.33% on February 6, 2019, 33.33% on February 6, 2020 and 33.33% on February 6, 2021.
- F4The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.